Phase II study of avelumab and trastuzumab with FOLFOX chemotherapy in previously untreated HER2-amplified metastatic gastroesophageal adenocarcinoma

Abstract Background Trastuzumab and multiagent chemotherapy have been the standard of care for the 20-30% of metastatic gastric and esophageal adenocarcinomas that overexpress HER2. Preclinical data show that trastuzumab requires a functional adaptive immune system for efficacy, suggesting synergy o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The oncologist (Dayton, Ohio) Jg. 30; H. 7
Hauptverfasser:	Lee, Michael S, Chao, Joseph, Mulcahy, Mary F, Kasi, Pashtoon M, Alistar, Angela T, Mukherjee, Sarbajit, Akce, Mehmet, Moore, Dominic T, McRee, Autumn J, Somasundaram, Ashwin
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	US Oxford University Press 01.07.2025
Schlagworte:	Adenocarcinoma Adenocarcinoma - drug therapy Adenocarcinoma - genetics Adenocarcinoma - pathology Adult Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - pharmacology Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Care and treatment Chemotherapy Clinical Trial Results Drug therapy Esophageal cancer Esophageal Neoplasms - drug therapy Esophageal Neoplasms - genetics Esophageal Neoplasms - pathology Female Fluorouracil - pharmacology Fluorouracil - therapeutic use Humans Leucovorin - pharmacology Leucovorin - therapeutic use Male Middle Aged Organoplatinum Compounds - pharmacology Organoplatinum Compounds - therapeutic use Pharmacology, Experimental Physiological aspects Receptor, ErbB-2 - genetics Stomach cancer Stomach Neoplasms - drug therapy Stomach Neoplasms - genetics Stomach Neoplasms - pathology Trastuzumab - administration & dosage Trastuzumab - pharmacology Trastuzumab - therapeutic use United States trastuzumab esophageal cancer gastric cancer HER2 immunotherapy
ISSN:	1083-7159, 1549-490X, 1549-490X
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!